Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
ASH 2016 - Multiple Myeloma
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
PREAMBLE: Real-World Efficacy Analyses in Multiple Myeloma Patients with One Line of Prior Therapy
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Retreatment with Daratumumab and Pomalidomide Among Refractory Patients with Multiple Myeloma
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Budget Impact Analysis of Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Meta-Analysis to Compare Efficacy of Treatment Regimens for Relapsed/Refractory Multiple Myeloma Patients
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Real-World Trends in Treatment Use, Healthcare Costs, and Overall Survival Among Patients with Multiple Myeloma
Read More
Conference Correspondent
,
ASH 2016 - Multiple Myeloma
Pomalidomide and Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma
Read More
1
2
Page 2 of 2
Results 11 - 19 of 19